BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 28825143)

  • 1. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
    Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
    Deng M; Chen HH; Zhu X; Luo M; Zhang K; Xu CJ; Hu KM; Cheng P; Zhou JJ; Zheng S; Chen YD
    Int J Cancer; 2019 Sep; 145(6):1517-1528. PubMed ID: 30720863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis of PALB2 gene in French breast cancer families.
    Damiola F; Schultz I; Barjhoux L; Sornin V; Dondon MG; Eon-Marchais S; Marcou M; ; Caron O; Gauthier-Villars M; de Pauw A; Luporsi E; Berthet P; Delnatte C; Bonadona V; Maugard C; Pujol P; Lasset C; Longy M; Bignon YJ; Fricker JP; Andrieu N; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Muller D
    Breast Cancer Res Treat; 2015 Dec; 154(3):463-71. PubMed ID: 26564480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel germline PALB2 truncating mutations in African American breast cancer patients.
    Zheng Y; Zhang J; Niu Q; Huo D; Olopade OI
    Cancer; 2012 Mar; 118(5):1362-70. PubMed ID: 21932393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
    Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
    Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Apr; 114(3):457-62. PubMed ID: 18446436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine.
    Myszka A; Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
    Fam Cancer; 2018 Jul; 17(3):345-349. PubMed ID: 29052111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.
    Dansonka-Mieszkowska A; Kluska A; Moes J; Dabrowska M; Nowakowska D; Niwinska A; Derlatka P; Cendrowski K; Kupryjanczyk J
    BMC Med Genet; 2010 Feb; 11():20. PubMed ID: 20122277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
    Hellebrand H; Sutter C; Honisch E; Gross E; Wappenschmidt B; Schem C; Deissler H; Ditsch N; Gress V; Kiechle M; Bartram CR; Schmutzler RK; Niederacher D; Arnold N; Meindl A
    Hum Mutat; 2011 Jun; 32(6):E2176-88. PubMed ID: 21618343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
    Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of PALB2-associated breast cancers.
    Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
    J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
    Downs B; Kim YC; Xiao F; Snyder C; Chen P; Fleissner EA; Becirovic D; Wen H; Sherman S; Cowan KH; Lynch HT; Wang SM
    Breast Cancer Res Treat; 2015 May; 151(1):219-24. PubMed ID: 25833210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.